J&J multiple myeloma drug succeeds in first-line combination study

(Reuters) – Johnson & Johnson’s blockbuster multiple myeloma drug Darzalex when added to a standard therapy regimen reduced the risk of disease progression or death by 50 percent compared with the standard therapy alone in patients not previously treated for the blood cancer, according to data released on Tuesday.


Source: Reuters Health

Roche, AbbVie leukemia drug superior to older medicine in study

(Reuters) – Patients with a type of leukemia that had relapsed who received the new drug Venclexta in combination with Rituxan went significantly longer without the disease worsening than those treated with Rituxan and Treanda, according to interim results from a pivotal late stage study released on Tuesday.


Source: Reuters Health